Internal Medicine, Endocrinology, Diabetes, & Metabolism · Boston, MA
NPI
1619924941
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
3
Medicare group memberships
Hospitals
4
Hospital affiliations
1 Joslin Pl, The Joslin Clinic
Boston, MA, 02215
Phone (617) 732-2476
Groups this clinician bills Medicare through
Medicare paid, 2024
$62K
1,118 services
Medicare patients, 2024
446
Average age 75
Drug cost, 2024
$2.2M
5,050 prescriptions
Company payments, 2025
$1,000
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Lyle D Mitzner was code 99214 (office e&m - established), 395 times for 272 patients. In total Lyle D Mitzner billed 1,118 services in 17 codes, and Medicare paid $62K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-09-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 395 | 272 | $76.49 | $30K |
| 95251 Test - Miscellaneous | Facility | 231 | 158 | $28.21 | $6,516 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 185 | 160 | $13.05 | $2,415 |
| 99232 Hospital E&M - Subsequent | Facility | 56 | 44 | $65.59 | $3,673 |
| 99214 Office E&M - Established | Office | 46 | 39 | $102.51 | $4,716 |
| 99222 Hospital E&M - Initial | Facility | 44 | 43 | $102.14 | $4,494 |
| 99231 Hospital E&M - Subsequent | Facility | 37 | 31 | $40.97 | $1,516 |
| 99215 Office E&M - Established | Facility | 26 | 26 | $112.17 | $2,916 |
| 99221 Hospital E&M - Initial | Facility | 20 | 20 | $58.23 | $1,165 |
| 99443 Telephone Services | Office | 20 | 17 | $97.09 | $1,942 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 17 | 17 | $13.81 | $235 |
| 99213 Office E&M - Established | Facility | 13 | 13 | $46.68 | $607 |
By year: 2022 $117K for 5,102 services; 2023 $65K for 956 services; 2024 $62K for 1,118 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 371 | 265 | $9.57 | $3,551 |
| 80061 Clinical Chemistry | 369 | 264 | $13.20 | $4,870 |
| 80051 Clinical Chemistry | 367 | 263 | $6.91 | $2,535 |
| 82565 Clinical Chemistry | 367 | 263 | $5.05 | $1,852 |
| 36415 Venipuncture Blood Collection | 366 | 263 | $2.96 | $1,084 |
| 84520 Clinical Chemistry | 366 | 263 | $3.90 | $1,427 |
| 84443 Clinical Chemistry | 365 | 260 | $16.55 | $6,042 |
| 80076 Clinical Chemistry | 354 | 253 | $8.05 | $2,851 |
| 82570 Clinical Chemistry | 341 | 248 | $5.11 | $1,742 |
| 82043 Clinical Chemistry | 340 | 247 | $5.69 | $1,936 |
Medicare prescription drug claims, 2024
In 2024, the drug Lyle D Mitzner prescribed most often to Medicare patients was Ozempic (Semaglutide), with 310 prescriptions and refills. In total Lyle D Mitzner wrote 5,050 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 310 | 549 | 77 | $515K |
| Metformin Hcl Generic | 267 | 722 | 86 | $2,340 |
| Metformin Hcl Er Metformin Hcl | 225 | 613 | 70 | $3,465 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 212 | 527 | 71 | $37K |
| Levothyroxine Sodium Generic | 193 | 498 | 47 | $2,161 |
| Atorvastatin Calcium Generic | 187 | 509 | 61 | $2,803 |
| Trulicity Dulaglutide | 178 | 342 | 48 | $331K |
| Rosuvastatin Calcium Generic | 138 | 340 | 39 | $3,596 |
| Novolog Flexpen Insulin Aspart | 136 | 259 | 57 | $41K |
| Mounjaro Tirzepatide | 119 | 188 | 25 | $199K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 114 | 293 | 49 | $18K |
| Tresiba Flextouch U-100 Insulin Degludec | 112 | 255 | 34 | $72K |
| Jardiance Empagliflozin | 110 | 213 | 26 | $120K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 109 | 239 | 33 | $60K |
| Lisinopril Generic | 101 | 285 | 35 | $987 |
Brand drugs: 2,371 claims; generic drugs: 2,130 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Lyle D Mitzner $1,000 ($1,000 in general payments such as food, travel and fees) from 2 companies. The largest payer was Merck Healthcare KGaA with $700.
| Company | Payments | Amount |
|---|---|---|
| Merck Healthcare KGaA | 2 | $700 |
| Chiesi USA, Inc. | 1 | $300 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.